ROCKET AF
- 14,000 participants
- 7 sites in New Zealand
Study Comparing Rivaroxaban (study drug) with Warfarin in patients being treated for non-Valvular Atrial Fibrillation.
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation.
The main aim of this study is to demonstrate that rivaroxaban (study drug), a direct factor Xa inhibitor, is as good as the standard treatment warfarin for the prevention of thromboembolic events in subjects with non-valvular atrial fibrillation.